MOTS-c vs CJC-1295: a metabolism peptide vs a growth-hormone peptide
MOTS-c and CJC-1295 are often searched together but they're entirely different tools. MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK and improves metabolism. CJC-1295 is a synthetic GHRH analog that raises growth hormone and IGF-1. Below: the side-by-side breakdown.
Side-by-side comparison
| Attribute | MOTS-c | CJC-1295 |
|---|---|---|
| Class | Mitochondrial-derived peptide (MDP) | GHRH analog (growth hormone secretagogue) |
| Length | 16 amino acids | 30 amino acids (CJC-1295 with DAC) |
| Origin | Encoded inside mitochondrial DNA (12S rRNA) | Synthetic modified GHRH peptide |
| Primary mechanism | AMPK activation in muscle, liver, fat | Stimulates pituitary release of growth hormone (GH) and IGF-1 |
| Main effect | Improved insulin sensitivity, glucose uptake, mitochondrial function | Elevated GH/IGF-1 — increased lean mass, recovery, fat loss |
| Studied for | Type 2 diabetes, obesity, NAFLD, sarcopenia, longevity | Body composition, recovery, anti-aging, GH deficiency (off-label) |
| Half-life | Short (minutes); requires repeat dosing | Long (~8 days) when bound with DAC; short (~30 min) without DAC |
| Effect on blood sugar | Lowers glucose, improves insulin sensitivity | Can raise blood glucose and worsen insulin sensitivity |
| Regulatory status | Research chemical only — not FDA approved | Research chemical only — not FDA approved (a related GHRH, tesamorelin, is) |
MOTS-c at a glance
MOTS-c signals through AMPK, the cell's master energy sensor. Studies focus on insulin sensitivity, prevention of diet-induced obesity, restored exercise capacity in aged mice, and protection against bone and muscle loss. It is not anabolic — it makes existing metabolic machinery more efficient.
CJC-1295 at a glance
CJC-1295 is a synthetic, longer-acting analog of growth hormone releasing hormone (GHRH). With the DAC modification its half-life is roughly 8 days, producing a sustained rise in endogenous GH and IGF-1. Research uses target body composition, recovery, and indirectly the same downstream effects as exogenous growth hormone — with a different side-effect profile (water retention, joint discomfort, glucose dysregulation at higher exposures).
Which one fits which goal?
- Metabolic syndrome, insulin resistance, fatty liver → MOTS-c is mechanistically aligned.
- Lean mass, recovery, IGF-1-driven goals → CJC-1295 is the GH-axis tool.
- Healthy aging → MOTS-c targets mitochondrial decline; CJC-1295 targets GH/IGF-1 decline. Different axes of aging.
- Risk of worsening blood sugar → CJC-1295 can raise glucose; MOTS-c lowers it.
For dosing, side effects, and regulatory status of MOTS-c, see safety and dosing. For mechanism depth, see what is MOTS-c.
Get the MOTS-c research digest
One short email a month with new studies, takeaways, and protocols. No spam.
Frequently asked questions
What's the difference between MOTS-c and CJC-1295?+
They're entirely different peptide classes. MOTS-c is a mitochondrial-derived peptide that improves metabolism by activating AMPK. CJC-1295 is a synthetic GHRH analog that triggers the pituitary to release growth hormone, raising GH and IGF-1.
Can you take MOTS-c and CJC-1295 together?+
There's no human safety data for the combination. Conceptually they target different goals (metabolic efficiency vs anabolic growth signaling) and even oppose each other on insulin sensitivity — CJC-1295 raises GH, which can worsen insulin resistance, while MOTS-c improves it. Stacking is research-only and not advisable without clinical supervision.
Is MOTS-c or CJC-1295 better for fat loss?+
Different mechanisms. CJC-1295 drives fat loss via elevated GH and lipolysis but may worsen blood sugar. MOTS-c drives fat loss via improved insulin sensitivity and fatty-acid oxidation. For metabolic-syndrome phenotypes, MOTS-c's mechanism is more aligned with the underlying problem.
Are MOTS-c and CJC-1295 both peptides?+
Yes, but very different ones. MOTS-c is a 16-amino-acid mitochondrial peptide produced naturally inside the body. CJC-1295 is a 30-amino-acid synthetic peptide modeled on GHRH (growth hormone releasing hormone), often modified with a Drug Affinity Complex (DAC) to extend its half-life.
References
- Lee C., Zeng J., Drew B.G., et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism, 2015. View source →
- Teichman S.L., Neale A., Lawrence B., et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GHRH analog. JCEM, 2006. View source →
- Reynolds J.C., Lai R.W., Woodhead J.S.T., et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nature Communications, 2021. View source →
Links open on PubMed or the original journal. Last reviewed dates reflect when our editorial team last verified each citation.